Status:
TERMINATED
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
Lead Sponsor:
Cougar Biotechnology, Inc.
Conditions:
Refractory Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma
Eligibility Criteria
Inclusion
- Advanced Multiple Myeloma.
- Progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (iMID), one alkylator, and bortezomib (VELCADE®).
- ECOG performance status of either 0 or 1.
Exclusion
- Prior chemotherapy with antimicrotubule agents
- Metastasis involving the brain or spinal cord
- Clinically significant lung or heart disease
- Abnormal electrocardiogram
- Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
- Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00912899
Start Date
December 1 2007
End Date
July 1 2010
Last Update
October 7 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA
Los Angeles, California, United States, 90024
2
St. Vincent's Comprehensive Cancer Center
New York, New York, United States, 10011
3
Weill Medical College of Cornell University
New York, New York, United States, 10021
4
Columbia Presbyterian Hospital
New York, New York, United States, 10032